CatalystFDA/Bio

Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint

Phase 3 trial miss triggers share decline, signaling negative clinical outcome.

What changed

Phase 3 trial miss triggers share decline, signaling negative clinical outcome.

Why it matters

Phase 3 trial miss triggers share decline, signaling negative clinical outcome. — impact context not separately stored; see What changed.

Sources